Ischemic endothelial cells

Ischemic endothelial cells are vascular cells that have been compromised by a lack of blood flow, leading to oxygen and nutrient deprivation (Source: PMID: 22534658). This pathological state triggers the stabilization of Hypoxia-inducible factor 1-alpha (HIF-1α), which promotes the expression of Vascular endothelial growth factor (VEGF) to initiate compensatory angiogenesis (Source: PMID: 11290332). These cells undergo a transition from a homeostatic state to a dysfunctional one, characterized by impaired nitric oxide synthesis, increased oxidative stress, and the upregulation of adhesion molecules like ICAM-1 and VCAM-1 (Source: PMID: 10739540). In clinical conditions such as myocardial infarction and stroke, ischemic endothelial cells are central to the injury process and the subsequent inflammatory response. Therapeutic interventions often target these cells to restore vascular integrity, promote revascularization, or protect against ischemia-reperfusion injury. While Ischemic endothelial cells refers to a cell state rather than a single molecule, the specific receptors and signaling pathways within these cells are major focuses for drug development in cardiovascular and regenerative medicine (Source: StatPearls, Endothelial Dysfunction).

Other names

Hypoxic endothelial cellsIschemia-challenged endothelial cellsIschemic vascular endotheliumDysfunctional ischemic endothelium

Therapeutic agents act by modulating specific molecular pathways within the ischemic cell, such as activating pro-survival and pro-angiogenic signaling (e.g., VEGF/VEGFR signaling), restoring nitric oxide production via eNOS activation, or inhibiting inflammatory adhesion molecules to prevent leukocyte infiltration (Source: PMID: 22534658, 10739540).